瑞波西汀与西酞普兰治疗老年抑郁症的对照研究

目的评价瑞波西汀治疗首发老年抑郁症的疗效和安全性。方法采用随机、单盲、平行对照方法。受试者分别口服瑞波西汀胶囊8mg/d（4mg/d起,周增至治疗量）或西酞普兰40mg/d（20mg/d起,周增11至治疗量）。采用HAMD、HAMA、CGI及TESS评定疗效及不良反应。结果共搜集符合入组标准的老年抑郁症80例,其中瑞波西汀组40例（试验组）,因药物不良反应脱落1例,因其他原因中途退出1例,实际完成38例。西酞普兰组40例（对照组）。经治疗6周后,瑞波西汀组HAMD、HAMA总分明显下降,与治疗基线相比差异有统计学意义（P〈0.01）,但两组间相比差异则无统计学意义（P〉0.05）;瑞波西汀组有效率（HAMD减分率≥50%）为76.3%,西酞普兰组为77.5%,两组间相比差异无统计学意义（P〉0.05）;临床治愈率（HAMD、HAMA总分≤8）瑞波西汀组为57.9%,西酞普兰组为57.5%,两组间差异无统计学意义（P〉0.05）;两组间CGI评分差异亦无统计学意义。安全性分析显示,两组不良反应的症状和发生率相比差异均无统计学意义。结论瑞波西汀治疗首发老年期抑郁症的疗效与西酞普兰相当,安全性高,不良反应较少,是药物治疗老年抑郁症的新选择。     

西酞普兰与氟西汀治疗抑郁症对照研究

目的：验证西酞普兰治疗抑郁症的疗效及安全性。方法：按前瞻性，随机、单盲法将56例抑郁症患者分为西酞普兰组与氟西汀组。疗程6周。在疗前、治疗1、2、6周用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)评定疗效，用副反应量表(TESS)、实验室检查及体检评价安全性。结果：两组总体疗效相当。但2周末时HAMD评分及减分率、HAMA评分两组问差异有显著性，说明西酞普兰起效较快。两组不良反应均较轻，安全性好。结论：西酞普兰是一种安全有效的抗抑郁药，耐受性及依从性好。     

西酞普兰与氟西汀治疗抑郁症对照研究

目的 评价西酞普兰与氟西汀治疗抑郁症的疗效及安全性。方法 将44例符合CCMD-3诊断标准的抑郁症患者随机分为西酞普兰组和氟西汀组，疗程6周，用汉密尔顿抑郁量表（HAMD）和副反应量表（TESS）评定疗效和不良反应。结果 两组总体疗效相当，有效率分别为88．9％和86．1％。但1周末时HAMD评分及减分率两组间差异有显著性，说明西酞普兰起效较快。两组不良反应均较轻，但西酞普兰组更轻。结论 西酞普兰是一种既有效又安全的SSRIs抗抑郁药物。     

西酞普兰与氟西汀治疗老年抑郁症对照研究

目的 比较西酞普兰和氟西汀治疗老年抑郁症的疗效及安全性.方法 将54例老年抑郁症患者随机分为西酞普兰组和氟西汀组,分别给予西酞普兰和氟西汀治疗,疗程6周.采用汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）及副反应量表（TESS）评定疗效和副反应.结果 2组总体疗效相当,显效率分别为82.3%和75.6%.但2周末时HAMD评分及减分率、HAMA评分2组间差异有显著性,说明西酞普兰起效较快.2组不良反应均较轻,安全性好.结论 西酞普兰是一种安全有效的抗抑郁药,能用于老年抑郁症患者.     

西酞普兰的临床应用——西酞普兰与氟西汀治疗抑郁症对照研究

目的：比较西酞普兰与氟西汀治疗抑郁症的疗效及不良反应。方法：57例抑郁症患者被随机分为西酞普兰组(29例)和氟西汀组(28例)进行为期6周的治疗。以汉密尔顿抑郁量表(HAMD)、副反应量表(TESS)于治疗前及治疗1、2、4、6周末分别评定疗效和不良反应。结果：西酞普兰组显效率为72．4％，氟西汀组为71．4％，两组间比较差异无显著性。两组HAMD评分于治疗1、2周末差异有显著性，提示西酞普兰起效较早。治疗后各周两组间TESS评分比较差异均无显著性。结论：西酞普兰和氟西汀均有良好的抗抑郁效果。西酞普兰具有起效早、不良反应小的优点。     

西酞普兰与氟西汀治疗抑郁症对照研究

目的 :比较西酞普兰与氟西汀治疗抑郁症的疗效及不良反应。　方法 :5 7例抑郁症患者被随机分为西酞普兰组 (2 9例 )和氟西汀组 (2 8例 )进行为期 6周的治疗。以汉密尔顿抑郁量表 (HAMD)、副反应量表 (TESS)于治疗前及治疗 1、2、4、6周末分别评定疗效和不良反应。　结果 :西酞普兰组显效率为 72 .4 % ,氟西汀组为 71.4 % ,两组间比较差异无显著性。两组HAMD评分于治疗 1、2周末差异有显著性 ,提示西酞普兰起效较早。治疗后各周两组间TESS评分比较差异均无显著性。　结论 :西酞普兰和氟西汀均有良好的抗抑郁效果。西酞普兰具有起效早、不良反应小的优点     

西酞普兰与氟西汀治疗抑郁症的对照研究

目的比较西酞普兰与氟西汀治疗抑郁症的疗效及不良反应。方法60例抑郁症患者被随机分为西酞普兰组(31例)和氟西汀级(29例)进行为期6周的治疗,以汉密尔顿抑郁量表(HAMD)、副反应量表(TESS)于治疗前及治疗1、2、4、6周末分别评定疗效和不良反应。结果西酞普兰组显效率为74.2%,氟西汀组为72.4%,两组间比较差异无显著性。两组HAMD评分治疗1、2周末差异有显著性,提示西酞普兰起效较早。治疗后各周两组间TESS评分比较差异均无显著性。结论西酞普兰与氟西汀相比较抗抑郁效果相当。西酞普兰具有起效早、不良反应小的优点。     

西酞普兰与帕罗西汀治疗抑郁症对照研究

目的:比较西酞普兰与帕罗西汀治疗抑郁症的临床疗效和不良反应。方法:将46例抑郁症患者随机分成两组,分别给予西酞普兰与帕罗西汀治疗。疗程8周。采用汉密尔顿抑郁量表(HAMD),汉密尔顿焦虑量表(HAMA),临床疗效总评量表(CGI)评定疗效,用副反应量表(TESS)及实验室检查评定不良反应。结果:西酞普兰组与帕罗西汀组疗效相似,不良反应均较轻,治疗2周时以西酞普兰组HAMD减分率显著较多。结论:西酞普兰治疗抑郁症起效快,疗效好,安全范围广。     

西酞普兰与米安色林治疗老年抑郁症对照研究

目的:比较西酞普兰与米安色林治疗老年抑郁症的疗效及安全性。方法:将106例老年抑郁症患者随机分为西酞普兰组和米安色林组,疗程6周。采用汉密尔顿抑郁量表(HAMD)评定临床疗效,副反应量表(TESS)评定不良反应。结果:西酞普兰组与米安色林组疗效相仿;疗后HAMD总分均有显著减少。西酞普兰显效快,不良反应小。结论:西酞普兰是治疗老年抑郁症较好的药物。     

丁螺环酮合并西酞普兰治疗伴躯体症状抑郁症的疗效观察

目的 探讨丁螺环酮合并西酞普兰治疗伴躯体症状抑郁症的疗效和安全性.方法 对60例伴躯体症状抑郁症患者随机分为研究组与对照组,研究组采用丁螺环酮合并西酞普兰治疗,对照组用西酞普兰治疗,治疗8周,两组分别在治疗2、4、6、8周采用汉密尔顿抑郁量表(HAMD)、临床疗效总评量表(CGI)评定疗效,以副反应症状量表(TESS)评定不良反应.结果 与对照组相比,研究组HAMD评分减分率显著增大,CGI评分显著降低,两组TESS评分相当.结论 丁螺环酮合并西酞普兰治疗伴躯体症状的抑郁症疗效较单用西酞普兰好,安全性较好.     

Sense of coherence as a predictor of subjective state of health: results of 4 years of follow-up of adults

A number of cross-sectional population studies have shown that a strong sense of coherence (SOC) is associated with various aspects of good perceived health. The association does not seem to be entirely attributable to underlying associations of SOC with other variables, such as age or level of education. OBJECTIVE: The aim of the study reported here was to determine whether SOC predicted subjective state of health. METHODS: The study was carried out as a two-way panel mail survey of 1976 individuals with 4 years interval for two collections of data. The statistical method used was multivariate cumulative logistic modeling. Age, initial subjective state of health, initial occupational training level, and initial degree of social integration were included as potential explanatory variables. RESULTS: A strong SOC predicted good health in women and men. CONCLUSIONS: SOC can be interpreted as an autonomous internal resource contributing to a favorable development of subjective state of health. SOC data should, however, be regarded as complementary to and not a substitute for information already known to be associated with increased risk of future ill health.     

Mechanism of action of tubocurarine on nicotinic cholinoreceptors of neurons of the sympathetic ganglia of rats

Tubocurarine (Tc) effect on membrane currents elicited by acetylcholine (ACh) was studied in isolated superior cervical ganglion neurons of rat using patch-clamp method in the whole-cell recording mode. The "use-dependent" block of ACh current by Tc was revealed in the experiments with ACh applications, indicating that Tc blocked the channels opened by ACh. Mean lifetime of Tc-open channel complex, tau, was found to be 9.8 +/- 0.5 s (n = 7) at -50 mV and 20-24 degrees C. tau exponentially increased with membrane hyperpolarization (e-fold change in tau corresponded to the membrane potential shift by 61 mV). Inhibition of the ACh-induced current by Tc (3-30 microM/1) was completely abolished by membrane depolarization to the level of 80-100 mV. Inhibition of ACh-induced current was augmented at increased ACh doses. It is concluded that the open channel block produced by Tc is likely to be the only mechanism for Tc action on nicotinic acetylcholine receptors in superior cervical ganglion neurons of rat.     

Bibliography of officers of department of mental hygiene

Psychiatric Quarterly -     

The effect of age of onset of PD on risk of dementia

Background Dementia occurs in the majority of patients with Parkinson’s disease (PD). Late onset of PD has been reported to be associated with a higher risk for dementia. However, age at onset (AAO) and age at baseline assessment are often correlated. The aim of this study was to explore whether AAO of PD symptoms is a risk factor for dementia independent of the general effect of age. Methods Two community-based studies of PD in New York (n = 281) and Rogaland county, Norway (n = 227) and two population-based groups of healthy elderly from New York (n = 180) and Odense, Denmark (n = 2414) were followed prospectively for 3–4 years and assessed for dementia according to DSM-IIIR. All PD and control cases underwent neurological examination and were followed with neurological and neuropsychological assessments. We used Cox proportional hazards regression based on three different time scales to explore the effect of AAO of PD on risk of dementia, adjusting for age at baseline and other demographic and clinical variables. Findings In both PD groups and in the pooled analyses, there was a significant effect of age at baseline assessment on the time to develop dementia, but there was no effect of AAO independent of age itself. Consistent with these results, there was no increased relative effect of age on the time to develop dementia in PD cases compared with controls. Interpretation This study shows that it is the general effect of age, rather than AAO that is associated with incident dementia in subjects with PD. Received in revised form: 22 December 2005